IDEXX Laboratories Inc. is experiencing a notable decline in stock value amid ongoing challenges in the veterinary sector.
IDEXX Laboratories Inc. (NASDAQ:IDXX) is facing a significant drop in its stock price, down 1.55% to close at CA$525.16. This downturn comes as the company grapples with persistent weaknesses in U.S. veterinary clinical visits, which have impacted its growth potential.
Investor takeaway: Investors should be cautious as IDEXX continues to face headwinds from declining clinical visits and foreign exchange pressures, despite its strong international performance.
Advertisement
IDEXX Laboratories Inc
IDXX.US
IDXX.US
IDEXX Laboratories Inc
WealthAwesomeMarket cap
$41.68B
P/E
37.2x
52W high
$769.98
52W low
$500.61
1W change
+2.29%
Beta
1.54
Analyst Price Targets
Based on 13 analysts covering IDXX · as of Sep 28, 2026
Wall Street analysts forecast IDXX stock price to rise 31.5% over the next 12 months.
Consensus
Buy3.62 / 5.00
Avg. Target
C$701.33
+31.5% Upside
Previously C$698.92 on Sep 17, 2026
Current Price
C$533.44
Last close
Analyst Breakdown (13 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IDXX's historical volatility
30-Day Vol
23.4%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-24.1%
Annualized drift
90d Mean
C$489.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$518.34 | C$478.15 – C$561.90 |
| 60 trading days | C$503.66 | C$449.34 – C$564.55 |
| 90 trading days | C$489.40 | C$425.56 – C$562.82 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
IDEXX stock falls 1.55% amid U.S. veterinary visit declines
The company's stock has underperformed, falling 16.8% over the past year compared to the industry's 2.7% growth.
Bull case
IDEXX's Companion Animal Group is showing resilience with recurring revenue growth and an expanding customer base, thanks to advancements in diagnostic technology.
Bear case
The decline in U.S. veterinary clinical visits and foreign exchange challenges may hinder IDEXX's growth, leading to a tough outlook.
Challenges in the U.S. Veterinary Market
Advertisement
IDEXX has been struggling with a decline in U.S. veterinary clinical visits, which fell about 1.3% in the second quarter of 2026. This trend is mainly driven by a 3.4% drop in wellness visits, which are crucial for the company's reference laboratory testing revenue. The ongoing weakness in clinical visits poses a significant constraint on IDEXX's growth potential, as management anticipates a continued decline in the second half of the year.
Foreign Exchange Pressures Impacting Revenue Outlook
The company’s global operations expose it to fluctuations in foreign currency exchange rates, which have recently created challenges for its revenue outlook. IDEXX's updated exchange-rate assumptions have led to a reduction in its full-year revenue estimates by $15 million, indicating that currency movements could further dampen reported revenue growth in the upcoming quarters.
Looking Ahead: Potential for Recovery
Despite the current challenges, IDEXX's Companion Animal Group continues to show promise with strong international performance and a growing customer base. The company is investing in expanding its commercial footprint and enhancing its diagnostic offerings, which could pave the way for recovery if U.S. clinical visit trends improve. However, investors should remain vigilant as external pressures persist.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
